4/A: Structure Therapeutics Insider Corrects Stock Option Exercise Price in Amended SEC Filing

Ma Yingli, Chief Technology Officer of Structure Therapeutics Inc., files an amendment to a Form 4, correcting the exercise price of stock options to reflect the price of Ordinary Shares rather than American Depositary Shares.

Summary

• Ma Yingli, the Chief Technology Officer of Structure Therapeutics Inc., filed an amended Form 4 with the SEC.
• The amendment corrects the exercise price of stock options granted on March 15, 2024.
• The original filing incorrectly stated the exercise price as that of American Depositary Shares (ADSs).
• The corrected filing clarifies that the exercise price is based on the fair market value per Ordinary Share on the grant date, which is derived from the trading price of the Issuer's ADSs.
• The stock option allows Ma Yingli to buy 91,494 Ordinary Shares at an exercise price of $11.75.
• 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.
• Each ADS represents three Ordinary Shares of the Issuer.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't contain any information that would significantly impact the company's valuation or investor sentiment. The correction itself is a positive sign of transparency.

Industry Context

This filing is a routine disclosure related to insider transactions and is required by the SEC to ensure transparency in the market. It provides information about the holdings and transactions of company insiders, allowing investors to monitor potential conflicts of interest or significant changes in ownership.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
• The vesting schedule described (1/4th after one year, then monthly) is a fairly standard vesting arrangement.
• Comparing the size of this option grant to similar companies would require analyzing the overall compensation packages of executives at peer companies like Amgen, Gilead Sciences, or Vertex Pharmaceuticals.

Stakeholder Impact

• The correction of the stock option exercise price ensures accurate information is available to shareholders.
• The vesting schedule incentivizes the CTO to remain with the company.

Key Dates